Last updated on August 2016

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of secukinumab on aortic vascular inflammation and cardiometabolic biomarkers after 12 weeks of treatment, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult subjects with moderate to severe chronic plaque-type psoriasis

Other Details:

Qualified participants will receive related medical examinations, study medication, and imaging studies at no cost, and may be eligible for compensation for their time and travel. Please call us for more information.

Find a site near you

Start Over

Mount Sinai St. Luke's

1090 Amsterdam Avenue, 11th Floor New York, NY USA
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.